Truist Financial’s Crescent Biopharma CBIO Stock Holding History

Truist Financial’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,010	Closed	-$176K	–	2621
2023 Q2	$176K	Hold	1,010	–	–	﹤0.01%	2459
2023 Q1	$127K	Buy	+1,010	New	+$227K	﹤0.01%	2482

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Truist Financial's CBIO Position: Q3 2023 in Review

Truist Financial sold out of Crescent Biopharma (CBIO) in Q3 2023, closing a stake of 1,010 shares — an estimated $176K sold.

Truist Financial first reported a position in CBIO in Q1 2023 and held it in 2 quarters. The position peaked at $176K in Q2 2023. 49 funds tracked by Wall St. Rank hold CBIO as of Q3 2023.

Truist Financial reported no remaining Crescent Biopharma position as of Q3 2023 after selling out during the quarter.
Truist Financial sold 1,010 Crescent Biopharma shares in Q3 2023, an estimated $176K.
Truist Financial first reported a position in Crescent Biopharma in Q1 2023 and held it in 2 quarters.
Truist Financial's Crescent Biopharma position peaked at $176K in Q2 2023.
49 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2023.

Based on Truist Financial's 13F filing for Q3 2023, filed 14 Nov 2023.